Abstract
3TC (GR109714X) is a new cytosine dideoxynucleoside analogue that has been shown to have in vitro activity against a variety of laboratory and clinical strains of HIV-1 including zidovudine (ZDV)-resistant isolates. Preclinical studies suggest that 3TC may have fewer adverse effects than other antiretroviral nucleoside analogues. An initial bioavailability study demonstrated that 3TC was rapidly and extensively absorbed following oral administration.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
